Provided by Tiger Trade Technology Pte. Ltd.

BioRestorative Therapies, Inc.

0.2706
+0.073937.57%
Volume:212.35M
Turnover:58.41M
Market Cap:6.27M
PE:-0.18
High:0.3200
Open:0.2588
Low:0.2184
Close:0.1967
52wk High:2.28
52wk Low:0.1900
Shares:23.16M
Float Shares:20.78M
Volume Ratio:40.42
T/O Rate:1021.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4754
EPS(LYR):-1.1565
ROE:-207.73%
ROA:-89.73%
PB:2.86
PE(LYR):-0.23

Loading ...

BRIEF-Biorestorative Expands Global Protection For Thermostem

Reuters
·
Yesterday

BioRestorative Therapies Says IP Australia Allowed ThermoStem Patent Application for 3D Brown Fat Stem Cell Aggregates

Reuters
·
Yesterday

BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

GlobeNewswire
·
Yesterday

BioRestorative Therapies Announces $5 Million Offering With Warrants Issued

Reuters
·
Feb 17

BioRestorative Therapies Raises $5 Million in Public Offering with Warrants Exercisable at $0.35

Reuters
·
Feb 14

BioRestorative Announces Closing of $5.0 Million Public Offering

THOMSON REUTERS
·
Feb 14

BioRestorative Therapies Prices $5 Million Offering With Warrants at $0.35

Reuters
·
Feb 12

BioRestorative Therapies Inc - Offering Priced at $0.35 per Share With Warrants

THOMSON REUTERS
·
Feb 12

Biorestorative Announces Positive Outcome From Type B Meeting With FDA

Reuters
·
Feb 11

BioRestorative Therapies Inc: Currently Anticipates That Phase 3 Trial Ind Submission Will Be Made in Second Half of 2026

THOMSON REUTERS
·
Feb 11

BioRestorative Announces Positive Outcome from Type B Meeting with FDA

GlobeNewswire
·
Feb 11

BioRestorative completes patient enrollment in Phase 2 trial of BTRX-100

TIPRANKS
·
Feb 10

BioRestorative Therapies schließt Patientenrekrutierung für Phase-2-Studie zu BRTX-100 bei chronischer lumbaler Bandscheibenerkrankung ab

Reuters
·
Feb 10

BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

GlobeNewswire
·
Feb 10

BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation

Reuters
·
Nov 22, 2025

BioRestorative Therapies files to sell 508,592 shares of common stock for holder

TIPRANKS
·
Nov 19, 2025

BioRestorative Therapies Inc - Type B Meeting Scheduled for Mid-December

THOMSON REUTERS
·
Nov 17, 2025

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

GlobeNewswire
·
Nov 17, 2025

BioRestorative Therapies Q3 EPS $(0.33) Beats $(0.36) Estimate, Sales $11.800K Miss $460.000K Estimate

Benzinga
·
Nov 13, 2025

BioRestorative Therapies Q3 Net Income USD -3 Million

THOMSON REUTERS
·
Nov 13, 2025